HC Wainwright Brokers Decrease Earnings Estimates for MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities researchers at HC Wainwright reduced their Q1 2026 earnings per share estimates for shares of Mirum Pharmaceuticals in a research note issued on Thursday, February 26th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their previous forecast of $0.02. HC Wainwright has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.63 EPS, FY2028 earnings at $2.47 EPS, FY2029 earnings at $4.59 EPS and FY2030 earnings at $7.07 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.Mirum Pharmaceuticals’s revenue for the quarter was up 49.8% compared to the same quarter last year. During the same period last year, the company earned $1.00 earnings per share.

MIRM has been the topic of several other research reports. Evercore reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. TD Cowen increased their price objective on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen lowered Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday. Leerink Partners lowered their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Citizens Jmp lowered their price target on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $114.92.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $92.29 on Monday. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $109.28. The business has a fifty day simple moving average of $93.40 and a 200 day simple moving average of $79.28. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of -192.27 and a beta of 0.52.

Institutional Trading of Mirum Pharmaceuticals

A number of large investors have recently made changes to their positions in MIRM. Emerald Advisers LLC lifted its position in Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after buying an additional 63,834 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $808,000. Candriam S.C.A. increased its holdings in shares of Mirum Pharmaceuticals by 8.0% in the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after purchasing an additional 30,021 shares during the last quarter. TimesSquare Capital Management LLC bought a new stake in shares of Mirum Pharmaceuticals during the third quarter worth approximately $22,041,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $503,000.

Insider Buying and Selling

In related news, CEO Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the completion of the sale, the chief executive officer directly owned 160,294 shares of the company’s stock, valued at $16,558,370.20. The trade was a 5.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Peter Radovich sold 3,143 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the completion of the sale, the chief operating officer directly owned 23,286 shares of the company’s stock, valued at approximately $2,239,880.34. This trade represents a 11.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 45,136 shares of company stock worth $4,352,029. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.